NOVAVAX INC (NVAX) research

NOVAVAX INC
ShareXLinkedInReddit
Sector
Biotechnology
Last price
$10.46
As of

NOVAVAX INC (NVAX): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-06.

As of . Source: SEC EDGAR filings for NVAX. Method and limitations.

SHARE THIS CARD

Share the NVAX intelligence card

A branded snapshot of NVAX: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion NVAX intelligence card preview
Post to X
COMPANY DOSSIER

See the full NVAX dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for NVAX on one page. Preview it with sample data, then open it live with a free account.

Preview the NVAX dossier

Active signals for NVAX

FREE, NO ACCOUNT

Every signal on NVAX, as it fires

You are seeing 5 of 22 signals recorded on NVAX since 2026-05-31.

The five above landed across 2 days. The other 17 were recorded on 3 other days. 14 of the 22 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in NVAX (2026Q2)

Manager / securityMarket value% portfolioQoQ
D. E. Shaw & Co., Inc.CUSIP 670002401 · 2026Q2$53.2M0.03%,
TWO SIGMA INVESTMENTS, LPCUSIP 670002401 · 2026Q2$38.5M0.03%,
COATUE MANAGEMENT LLCCUSIP 670002401 · 2026Q2$36.1M0.07%,
MILLENNIUM MANAGEMENT LLCCUSIP 670002401 · 2026Q2$16.7M0.01%,
CITADEL ADVISORS LLCCUSIP 670002401 · 2026Q2$16M0.00%,
Point72 Asset Management, L.P.CUSIP 670002401 · 2026Q2$6.3M0.01%,
Point72 Asset Management, L.P.CUSIP 670002AD6 · 2026Q2$5.2M0.01%,
RENAISSANCE TECHNOLOGIES LLCCUSIP 670002401 · 2026Q2$4.7M0.01%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, NVAX

NVAX against its peers

NVAX's operating margin of 40.3% ranks in the 97th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.

MetricNVAXPeer medianPercentilen
Revenue FY1.1B USD68.6M USD9115
Operating margin40.3%-153.5%9716
Net margin39.2%-165.6%9717
Return on equityn/a-50.6%n/a20
P / E4.1xn/an/a0

Peers (23): VIR, ZBIO, SEPN, CMPS, MESO, XNCR, NBTX, STOK, ZYME, FBRX, ABSI, LKFT, TSHA, BHVN, GHRS, RAPP, RXRX, AGIO, SRPT, NTLA, URGN, SNDX, PVLA. Left out: BRVE (no annual filing), GENB (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (NVAX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more NVAX signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to NVAXand get the insider, 13F, options, and confluence read in one view.

Preview the NVAX dossier